Updated: 2/27/2019

Pulmonary Hypertension Drugs

0%
Topic
Review Topic
0
0
N/A
N/A
Questions
4 4
0
0
0%
0%
Evidence
2 2
0
0
Overview
  • Mechanism
    • competitively antagonizes endothelin-1 receptors   
      • decreases pulmonary vascular resistance 
  • Clinical use
    • pulmonary hypertension
 

Please rate topic.

Average 3.0 of 2 Ratings

Questions (4)
Question locked
Sorry, this question is for
PEAK Premium Subscribers only
Upgrade to PEAK
Question locked
Sorry, this question is for
PEAK Premium Subscribers only
Upgrade to PEAK

(M1.PL.15.75) A 45-year-old woman with history of systemic sclerosis presents with new onset dyspnea, which is worsened with moderate exertion. She also complains of chest pain. An ECG was obtained, and showed right-axis deviation. Chest x-ray showed right ventricle hypertrophy. Given the patient's history and presentation, right heart catheterization was performed, which confirmed the suspected diagnosis of pulmonary artery hypertension. It is decided to start the patient on bosentan. Which of the following describes the method of action of bosentan? Tested Concept

QID: 106865
1

Endothelin receptor antagonist

77%

(86/112)

2

Endothelin receptor agonist

13%

(15/112)

3

Phosphodiesterase type 5 inhibitor

5%

(6/112)

4

Calcium channel blocker

4%

(4/112)

5

Anticoagulant

0%

(0/112)

M 1 D

Select Answer to see Preferred Response

(M1.PL.13.31) A 40-year-old woman with ongoing dyspnea returns to her physician for a follow-up appointment. After an abnormal echocardiogram and pulmonary function testing revealed an isolated reduction in DLCO, a right heart catheterization was ordered to confirm the physician's clinical suspicion. She has family members with similar findings and genetic testing revealed a mutation in the BMPR2 gene. A representative lesion from lung biopsy histology is shown in figure A. Given the patient's clinical presentation and test results, which of the following pharmacologic therapies will the physician most likely provide? Tested Concept

QID: 100834
FIGURES:
1

Plasmapheresis

0%

(0/52)

2

Inhibitor of nitric oxide

8%

(4/52)

3

Bronchodilator

10%

(5/52)

4

Immunosuppression

10%

(5/52)

5

Vasodilator

69%

(36/52)

M 3 D

Select Answer to see Preferred Response

Evidence (2)
Topic COMMENTS (0)
Private Note